Pα+ Psychedelic Bulletin #211: AbbVie Officially Enters Psychedelics; atai-Beckley’s 5-MeO-DMT Scores Breakthrough Therapy Designation; California Bill Signed

AbbVie has completed its acquisition of Gilgamesh Pharmaceuticals’ lead candidate, bretisilocin[1], the large pharmaceutical company announced last Friday. The associated press release described the drug as “a next-generation psychedelic compound.” See our earlier reporting for more: AbbVie to Acquire Gilgamesh’s Bretisilocin for Up to $1.2B The move sees AbbVie become the largest…

Source